MarketCap
Facebook
X
Telegram
Phathom Pharmaceuticals Financial Ratios 2025-2011 | PHAT
Brief overview of Phathom Pharmaceuticals's valuation and returns
Current figures are compared with the company's own five-year history for 2023–2025.
Key multiples at the end of the period are P/S 5.63x (median 6.7x), P/B 10.09x (median 6.75x). On average, this basket is 16.7% above its own five-year medians. The market is pricing in elevated future expectations.
The latest available business-quality ratios are ROE 50.5%, ROA -85.4%, ROCE 36.5%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
The PEG ratio is 1.06x, reflecting a relatively balanced link between valuation and growth.
Overall assessment
Phathom Pharmaceuticals's multiples are demanding relative to current business quality. Material improvement is needed to justify them.
Annual Financial Ratios Phathom Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-4.5 | -1.1 | -2.3 | -1.7 | -5.1 | -10.2 | -1.6 | - | - | - | - | - | - | - | - |
P/S |
5.6 | 6.7 | 691.1 | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-3.0 | -5.3 | -3.9 | -5.0 | -3.9 | -3.9 | -22.4 | -0.2 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
1.55 B | 705 M | 577 M | 426 M | 662 M | 1.12 B | 182 M | 2.19 M | - | - | - | - | - | - | - |
EBITDA per Share |
-2.19 | -4.38 | -3.25 | -4.39 | -3.64 | -3.66 | -9.34 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-4.7 | -8.6 | -1.7 | - | - | - | - | - | - | - | - | ||||
PEG |
1.06 | 0.17 | - | -0.21 | 0.0 | - | - | - | - | - | - | - | - | ||
P/B |
-2.2 | -1.5 | -6.5 | -4.6 | 10.1 | 6.7 | 1.7 | - | - | - | - | - | - | - | - |
P/CF |
-5.9 | -1.4 | -3.4 | -2.3 | -4.9 | -18.5 | -6.4 | - | - | - | - | - | - | - | - |
ROE % |
50.49 | 131.84 | 277.07 | 264.29 | -199.41 | -66.44 | -111.92 | - | - | - | - | - | - | - | - |
ROA % |
-85.37 | -88.37 | -48.71 | -119.97 | -75.96 | -43.74 | -99.20 | - | - | - | - | - | - | - | - |
ROCE % |
36.51 | 109.42 | 229.95 | 230.49 | -187.21 | -52.45 | -41.91 | - | - | - | - | - | - | - | - |
Current Ratio |
0.4 | 0.6 | 0.9 | 0.7 | 1.6 | 5.2 | 68.2 | - | - | - | - | - | - | - | - |
DSO |
121.9 | 133.6 | 438.1 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
70.5 | 101.1 | 1320.1 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
125.1 | 528.9 | 24695.4 | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
192.3 | 234.6 | 1758.2 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
67.2 | -294.3 | -22937.2 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Phathom Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.05 | -1.31 | - | -1.32 | -1.56 | -1.42 | - | -0.76 | -0.84 | -0.89 | - | -1.32 | -1.33 | -1.07 | - | -0.98 | -1 | -0.96 | -1.58 | -1.02 | -0.64 | -0.62 | -3.97 | -9.3 | -13.11 | -0.19 | -0.07 | -0.04 | -0.04 | -0.07 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -1.09 | - | -1.09 | -1.32 | -1.19 | - | -0.63 | -0.65 | -0.71 | - | -1.09 | -1.18 | -0.99 | - | -0.88 | -0.96 | -0.92 | -1.54 | -0.98 | -0.6 | -0.63 | -0.64 | -0.86 | -12.4 | -0.19 | -0.07 | -0.04 | -0.04 | -0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
138.02 | 158.45 | 140.64 | 383.94 | 581.51 | 309.65 | 52.48 | 245.83 | 195.89 | 1156.07 | 813.87 | 778.44 | 549.66 | -205.44 | -84.29 | -111.95 | -94.07 | -77.27 | -66.44 | -81.78 | -94.10 | -121.74 | -111.92 | -31.29 | 21.14 | 110.42 | 211.76 | 174.13 | 151.57 | 100.79 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-106.58 | -104.91 | -50.74 | -68.99 | -65.13 | -51.95 | -59.96 | -85.26 | -92.32 | -104.14 | -79.87 | -95.92 | -59.39 | -76.42 | -47.23 | -65.43 | -60.94 | -51.05 | -43.74 | -63.64 | -78.57 | -105.54 | -99.20 | -114.75 | -120.42 | -86.30 | -85.81 | -32.15 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
113.74 | 132.04 | 118.00 | 318.64 | 481.44 | 268.26 | 53.86 | 214.82 | 175.14 | 1003.30 | 709.34 | 677.31 | 484.34 | -190.44 | -79.19 | -106.18 | -91.06 | -74.63 | -64.69 | -44.58 | -30.43 | -56.54 | -46.59 | -4.64 | 18.96 | 105.18 | 205.32 | 170.25 | 149.41 | 99.60 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
0.4 | 0.5 | 0.6 | 0.7 | 0.6 | - | 0.8 | 0.9 | 1.1 | 0.6 | 0.7 | 0.9 | - | 1.3 | 1.6 | 1.8 | 2.6 | 3.0 | 2.9 | 2.9 | 2.9 | 2.9 | 8.8 | 8.8 | 8.8 | 8.8 | 0.4 | 0.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
101.2 | 120.2 | - | 89.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
59.7 | 78.1 | - | 102.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
141.5 | 271.1 | - | 286.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
160.9 | 198.3 | - | 191.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
19.4 | -72.7 | - | -94.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Phathom Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
